BridgeBio Pharma (BBIO) Operating Leases (2020 - 2026)

BridgeBio Pharma (BBIO) has 7 years of Operating Leases data on file, last reported at $14.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 189.24% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2026 stood at $14.2 million (up 189.24% YoY), and the FY2025 full-year result was $3.8 million, down 18.85% from the prior year.
• Operating Leases grew to $14.2 million in Q1 2026, from $3.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $15.5 million in Q1 2022 to a low of $3.8 million in Q4 2025.
• A 5-year average of $9.3 million and a median of $9.0 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 47.71% in 2024 and surged 189.24% in 2026, its largest moves.
• Tracing BBIO's Operating Leases over 5 years: stood at $12.3 million in 2022, then dropped by 26.83% to $9.0 million in 2023, then slumped by 47.71% to $4.7 million in 2024, then dropped by 18.85% to $3.8 million in 2025, then soared by 273.03% to $14.2 million in 2026.
• Business Quant data shows BBIO's Operating Leases at $14.2 million in Q1 2026, $3.8 million in Q4 2025, and $8.7 million in Q3 2025.